THERAPY DOSSIER · th-69de4538888a

Synthetic cationic antimicrobial peptide AWRK6 (SWVGKHGKKFGLKKHKKH)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30205524 ↗2018Reported benefit

A Synthetic Peptide AWRK6 Alleviates Lipopolysaccharide-Induced Liver Injury.

MouseEndotoxin/LPSKunmingFemaleIntraperitoneal injection in vivo; culture medium in vitro10 mg/kg in vivo; 20 to 200 micrograms/mL in vitro, with 20…1 hour after lipopolysaccharide administration

Model: Lipopolysaccharide-induced liver injury by intraperitoneal injection of LPS at 50 mg/kg; parallel in vitro model using HepG2 cells with LPS at 40 micrograms/mL

AWRK6 reversed LPS-induced elevation of alanine aminotransferase and inducible nitric oxide synthase and restored superoxide dismutase, reduced histological damage and neutrophil infiltration, lowered TUNEL-positive apoptosis with normalisation of cleaved caspase 9, Bax and Bcl-2, restored HepG2 vi…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…